Jupiter Neurosciences Expands CNS Pipeline with ALA-002 License

JUNS Jupiter Neurosciences Inc

$2.42 -5.10%

View chart & analysis →

DFTX -3.13% CMPS -2.52% HELP -2.39%

1. 1Jupiter Neurosciences (JUNS) has signed an exclusive U.S. license agreement with PharmaAla Biotech for ALA-002.
2. 2The ALA-002 deal, an MDDA-patented formulation, is worth up to $100 million including milestones and positions the company as a dual clinical-stage CNS company.
3. 3With this addition, ALA-002 joins the company's existing Phase 2 Parkinson's disease program, as discussed by the company's CEO and president in a video interview with IPO Edge.

Source Ipo Edge +1 · View original ↗

Today's 5 AI picks, all free

Nothing hidden: past picks and how they did against the S&P 500.

See today's picks →